Erasca

Erasca makes medicines to treat people with cancer. They target gene changes that cause tumors to grow. Their treatments aim to help patients live longer.

Stopping Tumors in Their Tracks

• ERAS-0015: Oral medicine targeting proteins that drive growth in multiple solid cancers.
• ERAS-4001: Drug candidate designed to block specific protein mutations while sparing healthy cells.
• ERAS-12: Biparatopic antibody that binds to two different spots on a protein to attack tumors.

Recent Strategic Moves

• Entered a license agreement with Guangzhou Joyo Pharmatech Co., Ltd. in May 2024 to develop cancer inhibitors.
• Partnered with Medshine Discovery Inc. in May 2024 to license technology for specific tumor treatments.
• Collaborated with Tango Therapeutics, Inc. in March 2026 to test combined drug therapies in trials.
• Signed a clinical trial supply agreement with Merck in May 2026 for immune therapy drug access.
• Notified Novartis Pharma AG in March 2026 of plans to terminate their development partnership.

The Precision Medicine Advantage

The company focuses on shutting down specific biological pathways linked to over five million new cancer cases annually. This strategy targets both the main drivers of disease and the routes cancer uses to resist treatment.

Key Financial Facts

• Net loss reached $183.4 million in Q1 2026, deepening 492% from $31 million in Q1 2025.
• In-process research and development expenses hit $150 million in Q1 2026 compared to zero the previous year.
• Market capitalization rose to $4.9 billion in Q1 2026, up 1,169% from $388 million year-over-year.
• Operating cash flow was negative $27.4 million in Q1 2026, a 13% improvement from Q1 2025.

Bottom Line

Erasca has evolved from early research into a clinical-stage firm managing multiple human trials for targeted cancer drugs. Its focus on broad-acting inhibitors positions the company to address large populations of patients with specific genetic mutations.